糖尿病腎症のすべて

出版社： 中山書店
著者：
発行日： 2012-10-25
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784521733821
電子書籍版： 2012-10-25 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,480 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,480 円(税込)

購入する

商品紹介

糖尿病腎症における成因の解明や病態への理解が進み，治療薬の選択や血糖・血圧・脂質管理に対し患者個人にあった配慮がなされるようになったため，透析導入患者の増加には歯止めがかかっている。本書では，診断・検査における新しい話題はもとより先頃改訂された『CKD診療ガイド2012』の内容を踏まえ，臨床医が明日からでも応用できる治療のヒントが満載となるようまとめたものである。

目次

  • 糖尿病腎症のすべて

    ―目次―

    第１章　腎症の総論
    　定義・概念・自然経過
    　疫学

    第２章　腎症の成因と病態生理
    　高血糖による細胞内代謝異常
    　RAGE，AGEs
    　酸化ストレス
    　微小炎症
    　血行動態的変化
    　細胞外基質蓄積と血管新生異常をもたらす分子異常
    　遺伝的要素，感受性遺伝子
    　ポドサイト障害

    第３章　腎症の病理
    　腎症の病理

    第４章　腎症の診断と病期分類
    　腎症の症状と診断
    　腎症の診断と評価（尿検査）
    　腎症の診断と評価（腎機能評価）
    　腎症の病期分類

    第５章　腎症の治療・管理・対策とそのエビデンス
    　糖尿病腎症治療概論―多数のremission例からみた治療・管理目標
    　血圧管理（１）
    　血圧管理（２）
    　脂質管理
    　食事療法
    　腎不全の合併症を伴う腎症の管理（１）
    　　―心腎連関の病態と治療のポイント
    　腎不全の合併症を伴う腎症の管理（２）
    　　―骨ミネラル代謝異常の病態と治療のポイント
    　腎不全の合併症を伴う腎症の管理（３）
    　　―腎性貧血の病態と治療のポイント
    　晩期腎症と透析療法の問題点
    　　―晩期の薬物療法と導入時期，血液か腹膜透析か？
    　腎移植・膵腎移植
    　薬物使用の注意点
    　腎症の対策・病診連携

    第６章　腎症のトピックス
    　(プロ)レニン受容体
    　Nrf2活性化薬
    　インクレチン関連薬への期待
    　尿酸
    　SIRT1
    　HIF-１
    　mTOR

    付録　尿検査機器一覧

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 腎症の総論

P.6 掲載の参考文献
1) Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936 ; 12 : 83-97.
PubMed
2) de Boer IH, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011 ; 305 : 2532-9.
PubMed
3) Rosenstock J, Raskin P. Early diabetic nephropathy : Assessment and potential therapeutic intervention. Diabetes Care 1986 ; 9 : 529-45.
PubMed
4) Adler AI, et al ; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 ; 63 : 225-31.
PubMed
5) Araki S, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005 ; 54 : 2983-7.
PubMed
6) de Galan BE, et al ; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009 ; 20 : 883-92.
 
7) Perkins BA, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007 ; 18 : 1353-61.
PubMed
8) Parving HH, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 1987 ; 294 : 1443-7.
PubMed
9) Skupien J, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 2012 May 23, online.
 
10) Pergola PE, et al ; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011 ; 365 : 327-36.
 
P.12 掲載の参考文献
1) 日本透析医学会. 年別透析導入患者の主要原疾患の推移. http://docs.jsdt.or.jp/overview/pdf2011/p12.pdf
 
2) 日本臨床内科医会調査研究グループ. 糖尿病性神経障害に関する調査研究 第3報 網膜症, 腎症, 足動脈拍動, 合併症終末像. 日本臨床内科医会会誌 2001 ; 16 : 383-402.
Medical*Online
3) Yokoyama H, et al. Microalbuminuria is common in Japanese type 2 diabetic patients : a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care 2007 ; 30 : 989-92.
 
4) Ohta M, et al. Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes. Diabet Med 2010 ; 27 : 1017-23.
PubMed
5) Katayama S, et al. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 1025-31.
PubMed
6) Ninomiya T, et al ; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009 ; 20 : 1813-21.
 
7) Retnakaran R, et al ; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes : U.K. Prospective Diabetes Study 74. Diabetes 2006 ; 55 : 1832-9.
 
8) Nelson RG, et al. Diabetic kidney disease in Pima Indians. Diabetes Care 1993 ; 16 : 335-41.
PubMed
9) Maeda S, et al. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl 2007 ; (106) : S43-8.
 
10) Maeda S, et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 2010 ; 6 : e1000842.
 
・ Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 ; 359 : 1577-89.
PubMed

2章 腎症の成因と病態生理

P.20 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Eng J Med 1993 ; 329 : 977-86.
 
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Ohkubo Y, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 ; 28 : 103-17.
PubMed
4) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
5) Fioretto P, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998 ; 339 : 69-75.
PubMed
6) Kitada M, et al. Molecular mechanisms of diabetic vascular complications. J Diabetes Invest 2010 ; 1 : 77-89.
 
7) Ishii H, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996 ; 272 : 728-31.
PubMed
8) Koya D, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKCβinhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000 ; 14 : 439-47.
 
9) Langham RG, et al. Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy : relationship to long-term glycaemic control. Diabetologia 2008 ; 51 : 668-74.
 
10) Tuttle KR, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005 ; 28 : 2686-90.
PubMed
11) Buse MG. Hexosamines, insulin resistance, and the complications of diabetes : current status. Am J Physiol Endocrinol Metab 2006 ; 290 : E1-8.
PubMed
12) Bohlender JM, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005 ; 289 : F645-59.
PubMed
13) Wendt T, et al. Glucose, glycation, and RAGE : implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003 ; 14 : 1383-95.
PubMed
14) Yamamoto Y, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice+. J Clin Invest 2001 ; 108 : 261-8.
PubMed
15) Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications : a new perspective on an old paradigm. Diabetes 1999 ; 48 : 1-9.
 
16) Brownlee M. The pathobiology of diabetic complications : a unifying mechanism. Diabetes 2005 ; 54 : 1615-25.
PubMed
17) Du X, et al. In+hibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003 ; 112 : 1049-57.
 
P.25 掲載の参考文献
1) Nagai R, et al. Significance of advanced glycation endproducts (AGEs) in aging-related disease. Anti-aging Med 2010 ; 7 : 112-9.
 
2) Tanaka N, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000 ; 275 : 25781-90.
 
3) Yamamoto Y, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001 ; 108 : 261-8.
PubMed
4) Myint KM, et al. RAGE control of diabetic nephropathy in a mouse model : effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006 ; 55 : 2510-22.
 
5) Yamamoto Y, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 2011 ; 186 : 3248-57.
PubMed
6) He M, et al. Receptor for advanced glycation end products binds phosphatidylserine and asists in the clearance of apoptotic cells. EMBO Rep 2011 ; 12 : 358-64.
 
7) Yamamoto Y, et al. RAGE-mediated inflammation and diabetic vascular complications. J Diabetes Invest 2011 ; 2 : 155-7.
 
8) Yonekura H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003 ; 370 : 1097-109.
PubMed
9) Yamamoto Y, et al. Assaying soluble forms of receptor for advanced glycation endproducts. Arterioscler Thromb Vasc Biol 2007 ; 27 : 33-4.
 
10) Win MT, et al. Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res 2012 ; 2012 : 894605.
PubMed
P.31 掲載の参考文献
1) Sonta T, et al. In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker. Biochem Biophys Res Commun 2005 ; 330 : 415-22.
PubMed
2) Koya D, et al. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003 ; 14 (8 Suppl 3) : S250-3.
 
3) Inoguchi T, et al. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 2007 ; 298 : 1398-400.
PubMed
4) Inoguchi T, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 2000 ; 49 : 1939-45.
PubMed
5) Inoguchi T, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes : role of vascular NAD (P) H oxidase. J Am Soc Nephrol 2003 ; 14 (8 Suppl 3) : S227-32.
 
6) Ohshiro Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice. Diabetes 2006 ; 55 : 3112-20.
PubMed
7) Gorin Y, et al. Nox4 NAD (P) H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005 ; 280 : 39616-26.
 
8) Maeda Y, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 2010 ; 299 : F1328-38.
PubMed
9) Inoguchi T, Nawata H. NAD (P) H oxidase activation : a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005 ; 6 : 495-501.
PubMed
10) Fujii M, et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD (P) H oxidase. Kidney Int 2010 ; 78 : 905-19.
PubMed
P.37 掲載の参考文献
1) Adler AI, et al ; UKPDS Group. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 ; 63 : 225-32.
PubMed
2) Hirata K, et al. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 1998 ; 41 : 185-92.
PubMed
3) Wada T, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000 ; 58 : 1492-9.
PubMed
4) Navarro-Gonzalez JF, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011 ; 7 : 327-40.
PubMed
5) Sugimoto H, et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli : glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997 ; 46 : 2075-81.
PubMed
6) Okada S, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003 ; 52 : 2586-93.
PubMed
7) 四方賢一, 宮本聡. 糖尿病性腎症の成因としてのmicroinflammation. 月刊糖尿病 2009 ; 1 : 43-9.
 
8) Usui HK, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007 ; 56 : 363-72.
PubMed
9) Miyamoto S, et al. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage : anti-inflammatory effect of cholecystokinin. Diabetes 2012 ; 61 : 897-907.
 
10) Kodera R, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011 ; 54 : 965-78.
 
P.45 掲載の参考文献
1) Ito S, et al. Strain vessel hypothesis : a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 2009 ; 32 : 115-21.
PubMed
2) Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury : chronic servo-control of renal perfusion pressure in rats. Hypertension 2004 ; 43 : 752-9.
PubMed
3) Ihara G, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria : effect of angiotensin II blockade. J Hypertens 2010 ; 28 : 2289-98.
PubMed
4) Theuer J, et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2002 ; 2 : 3.
PubMed
5) Mori T, et al. Molecular mechanisms and therapeutic strategies of chronic renal injury : physiological role of angiotensin II-induced oxidative stress in renal medulla. J Pharmacol Sci 2006 ; 100 : 2-8.
PubMed
6) Ichihara A, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004 ; 114 : 1128-35.
 
7) Kobori H, et al. The intrarenal renin-angiotensin system : from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007 ; 59 : 251-87.
 
P.53 掲載の参考文献
1) Ziyadeh FN, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000 ; 97 : 8015-20.
PubMed
2) Shibuya K, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005 ; 54 : 838-45.
PubMed
3) Abe H, et al. Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation. J Biol Chem 2004 ; 279 : 14201-6.
PubMed
4) Zeisberg M, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003 ; 9 : 964-8.
PubMed
5) Zeisberg EM, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007 ; 13 : 952-61.
PubMed
6) Kanasaki M, et al. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline : a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair 2011 ; 4 : 25.
PubMed
7) Takiyama Y, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin : a possible role of HIF-1α expression and oxygen metabolism. Diabetes 2011 ; 60 : 981-92.
 
8) Sugimoto H, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012 ; 18 : 396-404.
PubMed
9) Kanesaki Y, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005 ; 45 : 288-94.
PubMed
10) Veron D, et al. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 2011 ; 54 : 1227-41.
 
11) Nasu T, et al. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 2009 ; 58 : 2365-75.
 
12) Kosugi T, et al. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am J Physiol Renal Physiol 2010 ; 298 : F609-16.
PubMed
13) Mauer M, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009 ; 361 : 40-51.
PubMed
P.58 掲載の参考文献
1) Krolewski AS, et al. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987 ; 317 : 1390-8.
 
2) Maeda S, et al. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl 2007 ; (106) ; S43-8.
 
3) Maeda S, et al. A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 2010 ; 6 : e1000842.
 
4) Maeda S, et al. Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 2010 ; 59 : 2075-9.
PubMed
5) Freedman BI, et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet 2011 ; 7 : e1002150.
PubMed
P.64 掲載の参考文献
1) 淺沼克彦, 富野康日己. 腎糸球体上皮細胞 (ポドサイト) におけるアクチン骨格制御. 日本腎臓学会誌 2008 ; 50 : 532-9.
 
2) Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 2003 ; 7 : 255-9.
PubMed
3) 淺沼克彦, 富野康日己編著. エキスパートのための腎臓内科学. 中外医学社 ; 2009.
 
4) Welsh GI, Coward RJ. Podocytes, glucose and insulin. Curr Opin Nephrol Hypertens 2010 ; 19 : 379-84.
 
5) Campbell KN, et al. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev 2011 ; 7 : 3-7.
PubMed
6) Welsh GI, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010 ; 12 : 329-40.
 
7) Stieger N, et al. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab Res Rev 2011 ; 27 : 207-15.
PubMed

3章 腎症の病理

P.74 掲載の参考文献
1) Kimmelstiel P, Wilson C. Intercapillary lesions in glomeruli of kidney. Am J Pathol 1936 ; 12 : 83-97.
PubMed
2) Osterby R, et al. Diabetic glomerulopathy. Structural characteristics of the early and advanced stages. Diabetes 1983 ; 32 (Suppl 2) : 79-82.
 
3) Tervaert TW, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010 ; 21 : 556-63.
PubMed
4) Lane PH, et al. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993 ; 43 : 661-7.
PubMed
5) Pagtalunan ME, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997 ; 99 : 342-8.
PubMed
6) Toyoda M, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007 ; 56 : 2155-60.
PubMed
7) Moriya T, et al. Urinary albumin as an indicator of diabetic nephropathy lesions in Japanese type 2 diabetic patients. Nephron 2002 ; 91 : 292-9.
PubMed
8) Moriya T, et al. Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes. Kidney Int 2012 ; 81 : 486-93.
PubMed
9) Fioretto P, et al. Sequential renal biopsies in insulin-dependent diabetic patients : structural factors associated with clinical progression. Kidney Int 1995 ; 48 : 1929-35.
PubMed
10) Moriya T, et al. Renal structure as an indicator for development of albuminuria in normo-and microalbuminuric type 2 diabetic patients. Diabetes Res Clin Pract 2008 ; 82 : 298-304.
PubMed
11) Fioretto P, et al. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994 ; 43 : 1358-64.
PubMed
12) Fioretto P, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996 ; 39 : 1569-76.
PubMed
13) Fioretto P, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998 ; 339 : 69-75.
PubMed
14) Christensen PK, et al. Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. Nephrol Dial Transplant 2001 ; 16 : 2337-47.
PubMed
15) Wong TY, et al. Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 2002 ; 25 : 900-5.
 
16) Klein R, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients : the Renin-Angiotensin System Study. Diabetes 2005 ; 54 : 527-33.
 
17) Schwartz MM, et al. Renal pathology patterns in type II diabetes mellitus : relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 1998 ; 13 : 2547-52.
 
・ Churg J, et al. Diabetic glomerulosclerosis. In : Renal disease : classification and atlas of glomerular disease. Tokyo : Igaku-Shoin ; 1982, pp.226-39.
 
・ Mauer SM, et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984 ; 74 : 1143-55.
PubMed

4章 腎症の診断と病期分類

P.83 掲載の参考文献
1) 日本透析医学会編. わが国の慢性透析療法の現況 (2010年12月31日現在). 透析会誌 2012 ; 45 : 1-47.
 
2) 猪股茂樹ほか. 糖尿病性腎症の新しい早期診断基準. 糖尿病 2005 ; 48 : 757-9.
 
3) Adler AI, et al. Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 ; 63 : 225-32.
PubMed
P.88 掲載の参考文献
1) Gerstein HC, et al ; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001 ; 286 : 421-6.
 
2) Yokoyama H, et al. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004 ; 66 : 448-54.
PubMed
3) Yokoyama H, et al. Brachial-ankle pulse wave velocity measured automatically by oscillometric method is elevated in diabetic patients with incipient nephropathy. Diabet Med 2003 ; 20 : 942-5.
PubMed
4) Smith A, et al. Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. J Am Soc Nephrol 2005 ; 16 : 1069-75.
PubMed
5) Yokoyama H, et al. Risks for glomerular filtration rate decline in association with progression of albuminuria in type 2 diabetes. Nephrol Dial Transplant 2011 ; 26 : 2924-30.
PubMed
6) Maroni BJ, et al. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985 ; 27 : 58-65.
PubMed
7) 池森敦子ほか. 尿中肝臓型脂肪酸結合蛋白 (L-FABP). 日本臨牀 2010 ; 68 : 406-9.
 
P.93 掲載の参考文献
1) 折田義正. イヌリンクリアランス測定法. モダンメディア 2007 ; 53 : 11-7.
 
2) Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009 ; 53 : 982-92.
PubMed
3) 日本腎臓学会編. CKD診療ガイド 2012. 東京医学社 ; 2012.
 
4) 平成23年度厚生労働科学研究費補助金腎疾患対策研究事業「CKDの早期発見, 予防, 治療標準化, 進展阻止に関する調査研究」. 研究代表者 : 今井圓裕.
 
5) Macisaac RJ, et al. Estimating glomerular filtration rate in diabetes using serum cystatin C. Clin Biochem Rev 2011 ; 32 : 61-7.
PubMed
6) Horio M, et al. Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance. Clin Exp Nephrol 2011 ; 15 : 868-76.
PubMed
7) Merchant ML, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009 ; 20 : 2065-74.
PubMed
8) Yokoyama H, et al. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol 2009 ; 4 : 1432-40.
PubMed
P.97 掲載の参考文献
1) 糖尿病性腎症に関する合同委員会. 糖尿病性腎症病期分類厚生省案の改訂について. 糖尿病 2001 ; 44 ; 623.
 
2) 日本腎臓学会腎病理診断標準化委員会・日本腎病理協会編. 腎生検病理アトラス「腎生検病理診断標準化への指針」病理改訂版. 東京医学社 ; 2010.
 
3) National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis 2002 ; 39 (2 Suppl 1) : S1-266.
 
4) Levy AS, et al. Definition and classification of chronic kidney disease : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 2005 ; 67 : 2089-100.
 
5) 日本腎臓学会編. エビデンスに基づくCKD診療ガイドライン 2009. 東京医学社 ; 2009.
 
6) 日本腎臓学会編. CKD診療ガイド 2012. 東京医学社 ; 2012.
 
7) Yokoyama H, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes : the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009 ; 24 : 1212-9.
PubMed
8) Caramori ML, et al. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients : an indicator of more advanced glomerular lesions. Diabetes 2003 ; 52 : 1036-40.
PubMed
9) Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011 ; 20 : 246-57.
PubMed
10) Ninomiya T, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009 ; 20 : 1813-21.
PubMed
11) Yokoyama H, et al. Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in type 2 diabetes : JDDM study 16. Diabet Med 2008 ; 25 : 1426-32.
PubMed

5章 腎症の治療・管理・対策とそのエビデンス

P.105 掲載の参考文献
1) Parving HH, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) : rationale and study design. Nephrol Dial Transplant 2009 ; 24 : 1663-71.
PubMed
2) ACCORD Study Group, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1575-85.
 
3) ACCORD Study Group, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011 ; 364 : 818-28.
 
4) Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007 ; 3 : 486-92.
PubMed
5) Kuwabara A, et al. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia 2010 ; 53 : 2056-65.
PubMed
6) Nagase M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol 2010 ; 14 : 303-14.
PubMed
7) Lee SH, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009 ; 297 : F1381-90.
PubMed
8) Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010 ; 55 : 813-8.
PubMed
9) Pagtalunan ME, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997 ; 99 : 342-8.
PubMed
10) Sugawara A, et al. Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease. Endocr J 2010 ; 57 : 847-52.
 
11) Navarro-Gonzalez JF, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011 ; 7 : 327-40.
PubMed
12) Ohtomo S, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007 ; 72 : 1512-9.
 
13) Sarafidis PA, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes : a meta-analysis. Am J Kidney Dis 2010 ; 55 : 835-47.
PubMed
14) Palm F, et al. Dimethylarginine dimethylaminohydrolase (DDAH) : expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007 ; 293 : H3227-45.
PubMed
15) Schwedhelm E, et al. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011 ; 7 : 275-85.
PubMed
16) Yamagishi S, et al. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE) -related disorders. Med Hypotheses 2007 ; 69 : 666-8.
PubMed
17) Sharma K, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011 ; 22 : 1144-51.
PubMed
18) Pergola PE, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011 ; 365 : 327-36.
PubMed
19) Afshinnia F, et al. Weight loss and proteinuria : systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 2010 ; 25 : 1173-83.
PubMed
20) Buchwald H, et al. Bariatric surgery : a systematic review and meta-analysis. JAMA 2004 ; 292 : 1724-37.
PubMed
21) DePaula AL, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008 ; 22 : 706-16.
PubMed
P.111 掲載の参考文献
1) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 ; 329 : 977-86.
 
2) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
3) Shichiri M, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000 ; 23 (Suppl 2) : B21-9.
 
4) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
 
5) ACCORD Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
 
6) Gaede P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
PubMed
7) Araki S, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007 ; 56 : 1727-30.
PubMed
8) Fioretto P, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998 ; 339 : 69-75.
PubMed
9) Toyoda M, et al. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol 2012. (in press)
 
10) 鈴木大輔. 持効型溶解インスリン活用マニュアル-誰でもできるインスリン導入. 南江堂 ; 2011. pp.35-6.
 
P.116 掲載の参考文献
1) Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 ; 351 : 1755-62.
 
2) Barnett AH, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004 ; 351 : 1952-61.
PubMed
3) Uzu T, et al. Reduction of microalbuminuria in patients with type 2 diabetes : the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007 ; 30 : 1581-3.
PubMed
4) Araki S, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005 ; 54 : 2983-7.
PubMed
5) Rossing K, et al. Remission of nephrotic-range albuminuria reduces risk of endstage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005 ; 48 : 2241-7.
PubMed
P.120 掲載の参考文献
1) Taguma Y, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985 ; 313 : 1617-20.
PubMed
2) Lewis EJ, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993 ; 329 : 1456-62.
 
3) Ravid M, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993 ; 118 : 577-81.
PubMed
4) Ravid M, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998 ; 128 : 982-8.
PubMed
5) Konoshita T, et al. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006 ; 29 : 848-52.
PubMed
6) Konoshita T, et al. Genetic variant of the Renin-Angiotensin system and diabetes influences blood pressure response to Angiotensin receptor blockers. Diabetes Care 2009 ; 32 : 1485-90.
PubMed
7) Konoshita T, et al. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens 2010 ; 28 : 2156-60.
 
8) Ogihara T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks : candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008 ; 51 : 393-8.
PubMed
9) Kolesnyk I, et al. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009 ; 24 : 272-7.
PubMed
P.127 掲載の参考文献
1) Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep 2002 ; 4 : 278-85.
PubMed
2) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2009. 日本高血圧学会 ; 2009.
 
3) Law MR, et al. Value of low dose combination treatment with blood pressure lowering drugs : analysis of 354 randomised trials. BMJ 2003 ; 326 : 1427.
PubMed
4) Uzu T, et al. Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol 2009 ; 13 : 300-6.
PubMed
5) Bakris GL, et al. Effects of different ACE inhibitor combinations on albuminuria : results of the GUARD study. Kidney Int 2008 ; 73 : 1303-9.
PubMed
6) Jamerson K, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008 ; 359 : 2417-28.
 
7) Bakris GL, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH) : a prespecified secondary analysis of a randomised controlled trial. Lancet 2010 ; 375 : 1173-81.
PubMed
P.133 掲載の参考文献
1) Appel GB, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003 ; 26 : 1402-7.
PubMed
2) Tonelli M, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005 ; 112 : 171-8.
 
3) Tonolo G, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000 ; 30 : 980-7.
PubMed
4) Douglas K, et al. Meta-analysis : the effect of statins on albuminuria. Ann Intern Med 2006 ; 145 : 117-24.
PubMed
5) 蔵田英明ほか. HMG-CoA還元酵素阻害薬によるSTZ糖尿病ラットにおける糖尿病性腎病変進展抑制効果の検討. 糖尿病 1991 ; 34 : 97-103.
 
6) Szummer K, et al. Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011 ; 79 : 997-1004.
PubMed
7) Ansquer JC, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes : results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005 ; 45 : 485-93.
 
8) Keech A, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 2005 ; 366 : 1849-61.
 
9) ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.
 
10) Gojo A, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007 ; 568 : 242-7.
PubMed
P.138 掲載の参考文献
1) Araki S, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005 ; 54 : 2983-7.
PubMed
2) Araki S, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patient with type 2 diabetes. Diabetes 2007 ; 56 : 1727-30.
PubMed
3) de Zeeuw D, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy : lessons from RENAAL. Kidney Int 2004 ; 65 : 2309-20.
PubMed
4) de Zeeuw D, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004 ; 110 : 921-7.
PubMed
5) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン. 改訂第2版. 南江堂 ; 2007.
 
6) 日本腎臓学会編. エビデンスに基づくCKD診療ガイドライン 2009. 東京医学社 ; 2009.
 
7) 日本腎臓学会編. CKD診療ガイド 2012. 東京医学社 ; 2012.
 
8) Bakris GL. UpToDate ver 19.2, 2011.
 
P.145 掲載の参考文献
1) 赤井裕輝. 寛解を目標とした糖尿病性腎症治療のあり方. 富野康日己ほか編. Annual Review 腎臓 2011. 中外医学社 ; 2011. pp.207-14.
 
2) 赤井裕輝. 糖尿病性腎症point of no returnはどこにあるのか. 岡芳知ほか編. 糖尿病学 2003. 診断と治療社 ; 2003. pp.145-55.
 
3) 赤井裕輝ほか. 緩やかでよいが低蛋白食はやはり必要である. 糖尿病合併症 2005 ; 19 : 151-5.
 
P.152 掲載の参考文献
1) Booth GL, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people : a population-based retrospective cohort study. Lancet 2006 ; 368 : 29-36.
PubMed
2) Volz HC, et al. HMGB1 : the missing link between diabetes mellitus and heart fail-ure. Basic Res Cardiol 2010 ; 105 : 805-20.
 
3) Miki T, et al. Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 2009 ; 58 : 2863-72.
PubMed
4) Ronco C, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008 ; 52 : 1527-39.
PubMed
5) Wada M, et al. Chronic kidney disease and coronary artery vulnerable plaques. Clin J Am Soc Nephrol 2011 ; 6 : 2792-8.
PubMed
6) Yu M, et al. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011 ; 6 : 30-9.
PubMed
7) Joki N, et al. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997 ; 12 : 718-23.
PubMed
8) Chen SC, et al. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011 ; 6 : 2750-8.
PubMed
9) Takahashi Y, et al. Renal function after catheter ablation of atrial fibrillation. Circulation 2011 ; 124 : 2380-7.
PubMed
10) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : results of HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 ; 355 : 253-9.
PubMed
P.161 掲載の参考文献
1) Moe S, et al. Definition, evaluation, and classification of renal oeteodystrophy : a position statement from Kidney Disease : Inproving Global Outcomes (KDIGO). Kidney Int 2006 ; 69 : 1945-53.
 
2) Kraukauer JC, et al. Bone loss and bone turnover in diabetes. Diabetes 1995 ; 44 : 775-82.
 
3) Inaba M, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002 ; 39 : 1261-9.
 
4) Inaba M, et al. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005 ; 76 : 256-60.
PubMed
5) Terada M, et al. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 1998 ; 22 : 17-23.
PubMed
6) Inaba M, et al. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995 ; 10 : 1050-6.
 
7) Yoshida O, et al. Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 1995 ; 21 : 201-4.
PubMed
8) Tanaka H, et al. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009 ; 45 : 949-55.
PubMed
9) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 837-53.
 
10) Okuno S, et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 2007 ; 49 : 417-25.
PubMed
11) London GM, et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008 ; 19 : 1827-35.
 
P.167 掲載の参考文献
1) 2008年版日本透析医学会. 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 2008 ; 41 : 661-716.
 
2) 日本腎臓学会編. CKD診療ガイド 2012. 東京医学社 ; 2012. pp.79-81.
 
3) Mohanram A, et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004 ; 66 : 1131-8.
PubMed
4) Akizawa T, et al. Management of anemia in chronic kidney disease patients : baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin Exp Nephrol 2011 ; 15 : 248-57.
PubMed
5) Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 2007 ; 22 : 2900-8.
PubMed
6) Besarab A, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 ; 339 : 584-90.
PubMed
7) Drueke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006 ; 355 : 2071-84.
PubMed
8) Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 ; 355 : 2085-98.
PubMed
9) Skali H, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa : the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011 ; 124 : 2903-8.
PubMed
・ 深川雅史, 椿原美治編. 慢性腎臓病 (CKD) に伴う貧血-ガイドラインサポートハンドブック. 医薬ジャーナル社 ; 2009.
 
・ 深川雅史. 透析患者の貧血. 透析患者の病態へのアプローチ. 改訂2版. 金芳堂 ; 2011. pp.208-18.
 
P.171 掲載の参考文献
1) de Brito-Ashurst I, et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009 ; 20 : 2075-84.
PubMed
2) Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000 ; 35 (6 Suppl 2) : S1-140.
 
3) Akizawa T, et al ; CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD : a multicenter, randomized, controlled trial. Am J Kidney Dis 2009 ; 54 : 459-67.
 
4) Hemodialysis Adequancy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006 ; 48 Suppl 1 : S2-90.
 
5) Cooper BA, et al ; IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010 ; 363 : 609-19.
PubMed
6) 中井滋ほか. わが国の慢性透析療法の現況 (2007年12月31日現在). 日本透析医学会雑誌 2009 ; 42 : 1-45.
 
P.175 掲載の参考文献
1) 松尾清一ほか, 厚生労働省難治性疾患克服研究事業進行性腎障害に関する調査研究班難治性ネフローゼ症候群分科会. ネフローゼ症候群診療指針. 日腎会誌 2011 ; 53 : 78-122.
 
2) 日本腎臓学会編. CKD診療ガイド 2012. 東京医学社 ; 2012. pp.73-5.
 
3) ONTARGET Investigators, Yusuf S, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 ; 358 : 1547-59.
 
4) Keech A, et al ; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes
 
P.181 掲載の参考文献
1) 日本透析医学会. 図説 わが国の慢性透析療法の現況. http://www.jsdt.or.jp/overview_confirm.html
 
2) Collins AJ, et al. United States Renal Data System 2011 Annual Data Report : Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012 ; 59 (1 Suppl 1) : A7, e1-420.
 
3) 高原史郎ほか ; 日本臨床腎移植学会. 腎移植臨床登録集計報告 (2010) -2 2009年実施症例の集計報告 (2). 移植 2010 ; 45 : 595-607.
Medical*Online
4) UNOS. http://www.unos.org/
 
5) 馬場園哲也ほか. 糖尿病性腎不全に対する腎移植の予後に関する研究. 糖尿病 1995 ; 38 : 347-52.
 
6) 移植関係学会合同委員会, 膵臓移植中央調整委員会. 膵臓移植に関する実施要項. 2010年12月改訂.
 
7) International Pancreas Transplant Registry. http://www.iptr.umn.edu/
 
8) 日本臓器移植ネットワーク. http://www.jotnw.or.jp/
 
9) 日本膵・膵島移植研究会膵臓移植班. 本邦膵移植症例登録報告 (2010). 移植 2010 ; 45 : 641-6.
Medical*Online
10) 馬場園哲也ほか. 膵移植後のインスリン依存型糖尿病患者における膵内分泌機能. 糖尿病 1992 ; 35 : 909-17.
 
11) Fioretto P, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998 ; 339 : 69-75.
PubMed
12) Biesenbach G, et al. Progression of macrovascular diseases is reduced in type 1 diabetic patients after more than 5 years successful combined pancreas-kidney transplantation in comparison to kidney transplantation alone. Transpl Int 2005 ; 18 : 1054-60.
PubMed
13) 厚生労働省健康局. 健発0114第3号. 平成22年1月14日.
 
P.187 掲載の参考文献
1) 日本腎臓学会編. CKD診療ガイド 2012. 東京医学社 ; 2012.
 
2) Kume S, et al. Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodyalysis. J Diabetes Invest 2012 ; 3 : 298-301.
 
3) Biesenbach G, et al. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003 ; 20 : 642-5.
PubMed
4) Rose B, Post T. Clinical Physiology of Acid-Base and Electrolyte Disorders. 5th ed. McGraw-Hill ; 2000. pp.192-6.
 
5) Schneider V, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure : A population-based, nested case-control analysis. Am J Epidemiol 2006 ; 164 : 881-9.
PubMed
6) Kim SM, et al. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD : a quality improvement report. Am J Kidney Dis 2010 ; 55 : 1018-25.
PubMed
7) 対馬義人. ガドリニウム造影剤と腎性全身性線維症. 槇野博史, 秋澤忠男編. 腎疾患・透析最新の治療. 南江堂 ; 2011. pp.38-41.
 
8) 細谷龍男ほか. 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン. 日腎会誌 2009 ; 51 : 839-42.
 
9) 太田美由希ほか. 糖尿病腎症患者における薬物使用上の注意点. 腎と透析 2009 ; 67 : 228-32.
 
P.194 掲載の参考文献
1) 山崎勝也ほか. 糖尿病予防のための戦略研究課題 2 (J-DOIT2) とは何か-その意義と展望. プラクティス 2007 ; 24 : 417-23.
Medical*Online
2) 四方賢一ほか. DNETT-Japan. 日本臨牀 2008 ; 66 増刊号 : 511-4.
 
3) 斎藤知栄ほか. FROM-J. Pharma Medica 2010 ; 28 : 59-63.
Medical*Online
4) 前島洋平ほか. 厚生労働研究費補助金 腎疾患対策研究事業. 慢性腎臓病 (CKD) に関する普及啓発のあり方に関する研究. 平成22年度総括・分担研究報告書. 2011. pp.34-45.
 
5) 宇治原誠. 糖尿病における現状と課題. 医療 2008 ; 62 : 495-9.
Medical*Online
6) 傍島裕司ほか. 糖尿病地域連携パスにおける細小血管合併症の評価. プラクティス 2010 ; 27 : 407-14.
Medical*Online
7) Jayapaul MK, et al. The joint diabetic-renal clinic in clinical practice : 10 years of data from a District General Hospital. QJM 2006 ; 99 : 153-60.
PubMed
8) Inaguma D, et al. Effect of an educational program on the predialysis period for patients with chronic renal failure. Clin Exp Nephrol 2006 ; 10 : 274-8.
PubMed

6章 腎症のトピックス

P.202 掲載の参考文献
1) Nguyen G, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002 ; 109 : 1417-27.
PubMed
2) Schefe JH, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006 ; 99 : 1355-66.
PubMed
3) Matavelli LC, et al. (Pro) renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol 2010 ; 37 : 277-82.
PubMed
4) Cousin C, et al. Soluble form of the (pro) renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 2009 ; 53 : 1077-82.
PubMed
5) Ludwig J, et al. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J Biol Chem 1998 ; 273 : 10939-47.
PubMed
6) Deinum J, et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999 ; 42 : 1006-10.
PubMed
7) Ichihara A, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004 ; 114 : 1128-35.
 
8) Ichihara A, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006 ; 17 : 1950-61.
PubMed
9) Oshima Y, et al. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 2011 ; 22 : 2203-12.
PubMed
10) Cruciat CM, et al. Requirement of prorenin receptor and vacuolar H+ -ATPase-mediated acidification for Wnt signaling. Science 2010 ; 327 : 459-63.
PubMed
・ Kinouchi K, et al. The (pro) renin receptor/ATP6AP2 is essential for vacuolar H+ -ATPase assembly in murine cardiomyocytes. Circ Res 2010 ; 107 : 30-4.
PubMed
P.208 掲載の参考文献
1) Uruno A, Motohashi H. The Keap1-Nrf2 system as an iv vivo sensor for electrophiles. Nitric Oxide 2011 ; 25 ; 153-60.
 
2) Taguchi K, et al. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011 ; 16 : 123-40.
PubMed
3) 伊東健. Nrf2/Keap1酸化ストレス応答系. 日薬理誌 2011 ; 138 : 41-2.
Medical*Online
4) 伊東健. Keap1/Nrf2による酸化ストレス応答と疾患. 実験医学 2007 ; 25 : 224-30.
 
5) 宇留野晃ほか. ストレスと生体反応- Nrf2-Keap1システムによるストレス応答の制御. Diabetes Frontier 2010 ; 21 : 412-7.
Medical*Online
6) 黒河博文, 山本雅之. 酸化ストレスセンサー分子 Keap1阻害薬. 血管医学 2011 ; 12 : 321-8.
Medical*Online
7) Itoh K, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997 ; 236 : 313-22.
PubMed
8) 伊東健. Nrf2酸化ストレス応答系による病態制御. 生化学 2009 ; 81 : 447-55.
 
9) Yoh K, et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001 ; 60 : 1343-53.
 
10) Yoh K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008 ; 13 : 1159-70.
PubMed
11) Pergola PE, et al ; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011 ; 365 : 327-36.
 
12) BEAM Clinical Trials. gov番号 : NCT00811889.
 
13) Meyerら. 2010 ASN Renal Week報告.
 
・ Dartmouth Medicine Magazine, 2006 Winter. http://dartmed.dartmouth.edu/winter06/html/compound_interest.php
 
・ Honda T, et al. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998 ; 8 : 2711-4.
PubMed
・ Pergola PE, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 2011 ; 33 : 469-76.
PubMed
P.213 掲載の参考文献
1) Seino Y, et al. GIP and GLP-1, the two incretin hormones : similarities and differences. J Diabetes Invest 2010 ; 1 : 8-23.
 
2) Park CW, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007 ; 18 : 1227-38.
PubMed
3) Mentlein R. Dipeptidyl-peptidase IV (CD26) -role in the inactivation of regulatory peptides. Regul Pept 1999 ; 85 : 9-24.
PubMed
4) Yu M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003 ; 21 : 1125-35.
PubMed
5) Hirata K, et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009 ; 380 : 44-9.
PubMed
6) Gutzwiller JP, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004 ; 89 : 3055-61.
 
7) Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus : current and emerging agents. Drugs 2011 ; 71 : 1675-88.
PubMed
8) Yabe D, Seino Y. Liraglutide in Adults with Type 2 Diabetes : Global Perspective on Safety, Efficacy and Patient Preference. Clinical Medicine Insights : Endocrinology and Diabetes 2011 ; 4 : 47-62.
PubMed
9) Mega C, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011 : 162092.
 
10) Kodera R, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011 ; 54 : 965-78.
 
11) Liu WJ, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012 ; 340 : 248-55.
PubMed
12) Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011 ; 58 : 69-73.
PubMed
13) Jacobsen LV, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009 ; 68 : 898-905.
PubMed
14) Linnebjerg H, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007 ; 64 : 317-27.
PubMed
15) Lukashevich V, et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment : a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011 ; 13 : 947-54.
 
P.218 掲載の参考文献
1) Hovind P, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes : an inception cohort study. Diabetes 2009 ; 58 : 1668-71.
PubMed
2) Ficociello LH, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes : results of a 6-year follow-up. Diabetes Care 2010 ; 33 : 1337-43.
PubMed
3) Jalal DI, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes : findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant 2010 ; 25 : 1865-9.
PubMed
4) Siu YP, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006 ; 47 : 51-9.
PubMed
5) Kanbay M, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011 ; 6 : 1887-94.
PubMed
6) Kao MP, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011 ; 22 : 1382-9.
PubMed
7) Goicoechea M, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010 ; 5 : 1388-93.
PubMed
8) Kosugi T, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009 ; 297 : F481-8.
PubMed
9) Becker MA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 ; 353 : 2450-61.
 
10) Reinders MK, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009 ; 68 : 892-7.
 
P.224 掲載の参考文献
1) Colman RJ, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009 ; 325 : 201-4.
PubMed
2) Liang F, et al. SIRT1 and insulin resistance. Nat Rev Endocrinol 2009 ; 5 : 367-73.
PubMed
3) Tikoo K, et al. Change in histone H3 phosphorylation, MAP kinase p38, SIR2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008 ; 42 : 397-404.
PubMed
4) Chuang PY, et al. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011 ; 6 : e23566.
 
5) Kume S, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010 ; 120 : 1043-55.
 
6) He W, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 2010 ; 120 : 1056-68.
PubMed
7) Maeda S, et al. Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes. Clin Exp Nephrol 2011 ; 15 : 381-90.
PubMed
8) Kitada M, et al. Dietary restriction ameliorates diabetic nephropathy through antiinflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats : a model of type 2 diabetes. Exp Diabetes Res 2011 ; 2011 : 908185.
 
9) Tikoo K, et al. Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Lett 2007 ; 581 : 1071-8.
PubMed
10) Timmers S, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011 ; 14 : 612-22.
PubMed
・ Guarente L. Franklin H. Epstein Lecture : Sirtuins, aging, and medicine. N Engl J Med 2011 ; 364 : 2235-44.
 
P.230 掲載の参考文献
1) Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009 ; 24 : 97-106.
PubMed
2) Rosenberger C, et al. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant 2008 ; 23 : 3472-8.
PubMed
3) Haase VH. Pathophysiological Consequences of HIF Activation : HIF as a modulator of fibrosis. Ann N Y Acad Sci 2009 ; 1177 : 57-65.
PubMed
4) Rosenberger C, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008 ; 73 : 34-42.
PubMed
5) Ohtomo S, et al. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant 2008 ; 23 : 116-72.
 
6) Isoe T, et al. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int 2010 ; 78 : 48-59.
PubMed
7) Katavetin P, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 2006 ; 17 : 1405-13.
PubMed
8) Thangarajah H, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 2009 ; 106 : 13505-10.
PubMed
9) Schodel J, et al. Factor inhibiting HIF limits the expression of hypoxia-inducible genes in podocytes and distal tubular cells. Kidney Int 2010 ; 78 : 857-67.
PubMed
10) Wang Z, et al. Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells. Kidney Int 2011 ; 79 : 300-10.
 
P.235 掲載の参考文献
1) Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011 ; 23 : 744-55.
PubMed
2) 特集/細胞成長・増殖の司令塔mTORシグナル. 実験医学 2011 ; 29.
 
3) Inoki K, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011 : 121 : 2181-96.
PubMed
4) Godel M, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011 : 121 : 2197-209.
PubMed
5) Inoki K, Huber TB. Mammalian target of rapamycin signaling in the podocyte. Curr Opin Nephrol Hypertens 2012 ; 21 : 251-7.
PubMed
6) Asanuma K, et al. MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. FASEB J 2003 : 17 : 1165-7.
PubMed
7) Mizushima N, et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004 : 15 : 1101-11.
PubMed
8) Sato S, et al. Two types of autophagy in the podocytes in renal biopsy specimens : ultrastructural study. J Submicrosc Cytol Pathol 2006 : 38 : 167-74.
PubMed
9) Hartleben B, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010 : 120 : 1084-96.
PubMed

書評

最近チェックした商品履歴

Loading...